Global Fair Pricing Tensions

Posted by Ed Schoonveld on Thu, May 16, 2019

Pricing for prescription drugs has been a contentious issue around the world as payers and patients don’t understand the cause of high drug prices and are struggling with patient access. Particularly in middle- and low-income countries, affordability of drugs in cancer has become an important part of a dialogue between the World Health Organization, governments, non-governmental organizations and patient advocates. The WHO has organized several meetings to explore and drive resolutions for drug-pricing-related issues for patented and generic drugs.


>
Read More

Dangerous, Simple Drug Pricing Solutions

Posted by Ed Schoonveld on Thu, Mar 21, 2019

At a time when drug company CEOs are questioned in Congress and polarized U.S. Democrats and Republicans appear to unite in an intent to act on drug pricing, the industry needs to be very concerned. U.S. politicians and academics are exploring ways to satisfy public thirst for lower drug cost. The biggest danger in today’s Twitter world is the appeal of seemingly simple solutions such as a single-payer system, international price index, ICER and, recently, a three-part pricing model.


>
Read More

The Access Journey

Posted by Ed Schoonveld on Thu, Feb 21, 2019

How do we devise an optimal strategy to ensure patient access to our treatments in an age of value and affordability? How do we incorporate the impact of payers, medical communities, providers, prescribers and patients in a framework that helps us make trade-offs for development and commercialization decisions? It’s time to start the “access journey.”


>
Read More

Who Cares?

Posted by Ed Schoonveld on Tue, Feb 12, 2019

In my recent post, I described the underlying changes that are leading to today’s payer-empowered pharmaceutical environment. Now let’s consider the implications of these changes on the negotiation process.


>
Read More

The WHO Report and Access to Cancer Medicines

Posted by Ed Schoonveld on Tue, Feb 05, 2019

The World Health Organization’s recently published report, “Pricing of Cancer Medicines and its Impacts,” has elevated the issue to the agenda of the WHO’s executive board and is likely to ignite a lot of debate and some potential actions. While the report raises some very legitimate concerns related to access to anti-cancer drugs for patients, it also falls short of understanding the pharmaceutical industry environment. Rather than simply blaming the industry, it would be more productive to understand what’s standing in the way of collaboration to address patient needs and then jointly try to develop realistic programs to resolve it.


>
Read More